her2 generally refers to human epidermal growth factor receptor 2, her2(+++) suggests that the prognosis of cancer is relatively poor, prone to recurrence and metastasis, and belongs to the more serious situation; it also suggests that corresponding targeted drugs can be used, and it is necessary to actively comply with the doctor’s instructions for treatment. Her2 generally refers to human epidermal growth factor receptor 2, which is usually used in immunohistochemistry for breast cancer and gastric cancer. her2(++++) is the result of immunohistochemistry staining in pathology report, which shows strong positive expression of her2 gene, suggesting that the cancer cells proliferate faster, easy to recur and metastasize, and with a relatively poor prognosis. For this kind of patients, anti-her2 treatment is needed. At present, the commonly used drugs are trastuzumab, patuzumab, etc. If target resistance can be replaced with lapatinib, or pyrrolitinib combined with capecitabine can also be used for treatment. It is recommended that the patient actively follow the doctor’s instructions to cooperate with the treatment, the occurrence of uncomfortable symptoms timely consultation.